SeaSpine Holdings Corporation Announces Additions to Management Team

Tyler Lipschultz Named Vice President, Orthobiologics and Business Development

Laetitia Cousin Named Vice President, Regulatory, Clinical and Quality Assurance

VISTA, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (Nasdaq:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the addition of two experienced leaders in the spine industry to the Company's management team.

  • Tyler Lipschultz has been named Vice President, Orthobiologics and Business Development, effective July 20, 2015. Mr. Lipschultz will be responsible for Orthobiologics marketing and development, as well as business development for all of SeaSpine. Mr. Lipschultz has more than 25 years of sales, marketing, and operational leadership experience in spine and general orthopedic devices. Most recently he served as Executive Vice President of NuVasive, including four years leading Global Operations and prior, leading the Biologics organization. Over the course of his career, Mr. Lipschultz has also held global management roles at Spine Wave, VERTx, DePuy, Smith & Nephew, and Stryker. He has also served as an equity research analyst for Piper Jaffray where he focused his research on orthopedic and spinal markets.
  • Laetitia Cousin has been named Vice President, Regulatory, Clinical and Quality Assurance, effective July 27, 2015. Mrs. Cousin has nearly two decades of medical technology experience, primarily in regulatory affairs and quality assurance. For the past 16 years, Mrs. Cousin has held progressively senior positions at NuVasive. Most recently, she served as Vice President, Regulatory and Clinical Affairs, Quality Assurance. Additionally, Mrs. Cousin has demonstrated excellence in scaling, influencing, and strategically guiding global regulatory, quality, and clinical teams in the spinal device and tissue industry.

Mr. Lipschultz and Mrs. Cousin will be part of the senior leadership team reporting directly to Keith Valentine, President and Chief Executive Officer.

"We are pleased to welcome Tyler and Laety to SeaSpine," said Keith Valentine. "SeaSpine is assembling an exceptionally qualified management team with deep experience in spine and in broader medical technology. Our goal is to effectively scale our business and advance our market position in orthobiologics and spine implants through targeted investment and strong execution. These key management appointments are a testament to our commitment to achieving that goal. We look forward to leveraging our expanding leadership team's experience as we reposition for growth as an independent public company."

About SeaSpine

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal fusion hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development allows SeaSpine to offer our surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. These statements include the ability of SeaSpine's management team to successfully scale and grow the business and advance market position. These risks include but are not limited to: SeaSpine's ability to attract and retain senior management and other key personnel, which are necessary to operate its business successfully and execute carry out planned growth and operate the Company's business; delays, costs and difficulties related to SeaSpine's spin-off and the operation as a separate, publicly traded company; general economic and political conditions globally and in the markets in which SeaSpine does business; and other factors identified under the heading "Risk Factors" of SeaSpine's Form 10 Registration Statement, as amended, filed with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and, except as required by law, SeaSpine undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations Contact: Lynn Pieper or Leigh Salvo (415) 513-1281 ir@seaspine.comSource:SeaSpine